Comparative Pharmacology
Head-to-head clinical analysis: HC 4 versus LOCORTEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HC 4 versus LOCORTEN.
HC #4 vs LOCORTEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HC #4 is a complex homeopathic preparation with no well-defined molecular mechanism; it is believed to act via hormesis or placebo effects.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit prostaglandin and leukotriene synthesis, reduce cytokine release, and suppress immune cell activation.
Hydrocortisone 100-300 mg IV bolus, followed by 100-200 mg IV every 6 hours for 24-48 hours; then taper as clinically indicated.
For mild to moderate dermatoses: Apply a thin film to affected area twice daily. For severe dermatoses: Apply a thin film to affected area three to four times daily. Topical use only. Not for ophthalmic use.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10–14 hours). Extends to 24 hours in severe renal impairment (CrCl <30 mL/min); dose adjustment recommended.
100 hours (terminal). Clinical context: prolonged in hepatic impairment; single daily dosing sufficient for psoriasis.
Renal excretion of unchanged drug: 95%; fecal/biliary: <5%.
Renal: ~75% (inactive metabolites); biliary/fecal: ~25%. <1% unchanged.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid